Healthcare entity
Telix Pharmaceuticals is the most frequent co-covered peer, appearing in 2 of the 8 tracked stories. Sentiment skews less negative than the wider beat, at 13% negative against 25% across all 735 Healthcare stories in the same window. That works out to roughly 0.4 stories per week across a 140-day span. The busiest single day carried 2.
Last mentioned: Jul 27, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 25 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Telix Pharmaceuticals is the most frequent co-covered peer, appearing in 2 of the 8 tracked stories. Sentiment skews less negative than the wider beat, at 13% negative against 25% across all 735 Healthcare stories in the same window. That works out to roughly 0.4 stories per week across a 140-day span. The busiest single day carried 2. market-trends accounts for 4 of the 8 tracked stories, while 2 other categories carry the remainder. The average consequence score is 6, matching the 6 beat baseline for this window. Each story carries 3.4 original sources on average, compared with 3.7 for the broader beat in this window. This profile follows 8 Healthcare stories mentioning Novartis across the period from February 26, 2026 to July 15, 2026.
Computed from the 8 stories linked to this entity, with beat comparisons drawn from all 735 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Novartis. Shared-story counts are live from our verified record — not editorial picks.
Keytruda Patent Cliff
Merck faces the loss of exclusivity for its top-selling cancer immunotherapy.
Interim Analysis
Expected interim efficacy data from the larger global patient cohort.
Expected Closing
Anticipated completion of the acquisition following regulatory reviews.
Acquisition Announcement
Merck announces definitive agreement to buy Terns for $6.7 billion.
Official Rollout
Scotland officially begins screening all newborns for the rare muscle disease.
Primary Objectives Met
Announcement that Part 1 successfully validated safety and dosimetry profiles.
FY 2025 Earnings
Legend Biotech reports full-year financial results and 2026 strategic outlook.
Novartis Settlement
Novartis resolves its legal dispute with the estate over the commercial use of HeLa cells.
Data Evaluation
Expected first review of screening efficacy and treatment referral rates in Scotland.
Pipeline Update
Initial Phase 1 data released for solid tumor candidates in neuroendocrine carcinoma.
Scottish Policy Review
Scottish health officials evaluate the feasibility of independent implementation.
Manufacturing Milestone
Ghent facility reaches full operational capacity for commercial production.
Label Expansion
Carvykti receives FDA approval for earlier lines of multiple myeloma treatment.
Enrollment Milestone
Completion of patient enrollment for the Part 1 SELECT lead-in phase.
Study Initiation
Launch of the ProstACT Global Phase 3 study for mCRPC.
Clinical Advocacy
Intense campaigning by rare disease groups for the inclusion of SMA in UK-wide screening.
Thermo Fisher Settlement
A landmark confidential settlement is reached, setting a precedent for the industry.
First Major Lawsuit
The Lacks estate files suit against Thermo Fisher Scientific on the 70th anniversary of her death.
HeLa Immortality
Researchers discover the cells can reproduce indefinitely, creating the first immortal human cell line.
Cells Harvested
Henrietta Lacks' cervical cancer cells are taken without consent at Johns Hopkins.
Two of Australia’s most used MS therapies, Ocrevus and Kesimpta, face a PBS pricing review that could slash subsidies by 40–50%. Without coverage, patients could pay over $33,000 annually, jeopardizing treatment access for thousands.
Merck has reached a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion, securing a promising Phase 2 leukemia treatment. The cash deal is a strategic move to diversify Merck's oncology portfolio as it prepares for the 2028 patent expiration of its blockbuster drug Keytruda.
Scotland has officially become the first nation in the United Kingdom to implement routine newborn screening for a rare genetic muscle disease. This landmark policy shift aims to identify affected infants at birth, allowing for immediate intervention and treatment before the onset of irreversible physical symptoms.
Source: lancashiretelegraph.co.uk · echo-news.co.uk
Legend Biotech (LEGN) has released its full-year 2025 financial results, showcasing significant revenue growth driven by the continued commercial expansion of its lead CAR-T therapy, Carvykti. The company highlighted major manufacturing milestones and a strategic pivot toward solid tumor indications following a year of intensive market penetration in earlier lines of multiple myeloma treatment.
Source: manilatimes.net · manilatimes.net
Telix Pharmaceuticals has successfully met the primary objectives for Part 1 of its global Phase 3 ProstACT study, validating the safety and dosimetry of its lead therapeutic candidate, TLX591. This milestone de-risks the antibody-based radiopharmaceutical program and clears the path for the trial's continued expansion in metastatic castration-resistant prostate cancer.
Source: sydneysun.com · wallstreet-online.de
Voyager Technologies and Zevra Therapeutics are set to report Q4 2025 earnings, highlighting a critical juncture for gene therapy delivery and rare disease commercialization. Investors are prioritizing updates on the TRACER platform milestones and the market penetration of newly launched orphan drugs.
Source: Seeking Alpha · Seeking Alpha
Novartis has reached a confidential settlement with the estate of Henrietta Lacks, resolving claims that the pharmaceutical giant unjustly profited from her 'immortal' cell line. This agreement marks a major milestone in the ongoing legal and ethical reckoning over the historical exploitation of Black patients in medical research.
Lantheus Holdings and Heron Therapeutics both reported mixed fourth-quarter results for the 2025 fiscal year, balancing immediate commercial headwinds with aggressive long-term guidance. Both companies introduced fiscal year 2026 outlooks, signaling a strategic shift toward post-2025 growth catalysts and pipeline diversification.
Source: Seeking Alpha · Seeking Alpha
Novartis is linked from 8 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
